661 results match your criteria Glioblastoma Multiforme* Neurology


A case of high grade glioma following treatment of relapsing-remitting multiple sclerosis with fingolimod.

Neurol India 2020 Mar-Apr;68(2):478-480

Department of Neurology, School of Medicine, Inonu University, Malatya, Turkey.

Multiple sclerosis is a major cause of neurological disability, especially in young adults. There have been several case reports of an increased risk of cancer after long-term treatment for multiple sclerosis. Fingolimod is an immunomodulating agent used in the treatment of relapsing-remitting multiple sclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0028-3886.284361DOI Listing

Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.

J Control Release 2020 May 11;324:1-16. Epub 2020 May 11.

School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston B15 2TT, United Kingdom. Electronic address:

Glioblastoma multiforme (GBM) is impossible to fully remove surgically and almost always recurs at the borders of the resection cavity, while systemic delivery of therapeutic drug levels to the brain tumour is limited by the blood-brain barrier. This research describes the development of a novel formulation of Irinotecan-loaded Drug Eluting Seeds (iDES) for insertion into the margin of the GBM resection cavity to provide a sustained high local dose with reduced systemic toxicities. We used primary GBM cells from both the tumour core and Brain Around the Tumour tissue from recurrent GBM patients to demonstrate that irinotecan is more effective than temozolomide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2020.05.012DOI Listing

The Intratumoral Heterogeneity Reflects the Intertumoral Subtypes of Glioblastoma Multiforme: A Regional Immunohistochemistry Analysis.

Front Oncol 2020 24;10:494. Epub 2020 Apr 24.

Division of Neuropathology, Technische Universität München, München, Germany.

Glioblastoma multiforme (GBM) is the most frequent and aggressive primary brain tumor in adults. Despite extensive therapy the prognosis for GBM patients remains poor and the extraordinary therapy resistance has been attributed to intertumoral heterogeneity of glioblastoma. Different prognostic relevant GBM tumor subtypes have been identified based on their molecular profile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193089PMC

Imaging-AMARETTO: An Imaging Genomics Software Tool to Interrogate Multiomics Networks for Relevance to Radiography and Histopathology Imaging Biomarkers of Clinical Outcomes.

JCO Clin Cancer Inform 2020 May;4:421-435

Cell Circuits Program, Broad Institute of MIT and Harvard, Cambridge, MA.

Purpose: The availability of increasing volumes of multiomics, imaging, and clinical data in complex diseases such as cancer opens opportunities for the formulation and development of computational imaging genomics methods that can link multiomics, imaging, and clinical data.

Methods: Here, we present the Imaging-AMARETTO algorithms and software tools to systematically interrogate regulatory networks derived from multiomics data within and across related patient studies for their relevance to radiography and histopathology imaging features predicting clinical outcomes.

Results: To demonstrate its utility, we applied Imaging-AMARETTO to integrate three patient studies of brain tumors, specifically, multiomics with radiography imaging data from The Cancer Genome Atlas (TCGA) glioblastoma multiforme (GBM) and low-grade glioma (LGG) cohorts and transcriptomics with histopathology imaging data from the Ivy Glioblastoma Atlas Project (IvyGAP) GBM cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.19.00125DOI Listing

Protective effect of c-Myc/Rab7a signal pathway in glioblastoma cells under hypoxia.

Ann Transl Med 2020 Mar;8(6):283

Department of Neurosurgery, The Second Affiliated Hospital of Zhejiang University, Hangzhou 310009, China.

Background: Glioblastoma multiforme (GBM) is the most common primary brain tumor, and is associated with a poor prognosis. Hypoxia is prevalent in the microenvironment of GBM, and promotes tumorigenesis and resistance to anticancer therapy. However, its mechanism remains incompletely understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2020.02.173DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186680PMC

miR‑296‑3p promotes the proliferation of glioblastoma cells by targeting ICAT.

Mol Med Rep 2020 May 3;21(5):2151-2161. Epub 2020 Mar 3.

Department of Neurology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China.

MicroRNAs (miRNA/miRs) serve an important function in the regulation of gene expression, and have been indicated to mediate a number of cellular biological processes, including cell proliferation, the cell cycle, cell apoptosis and cell differentiation. The altered expression of miRNAs has been revealed to result in a variety of human diseases, including glioblastoma multiforme (GBM). The present study indicated an increase in miR‑296‑3p in glioma tumor types compared with normal brain, particularly in the samples from patients with high grade GBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mmr.2020.11011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115191PMC

Congenital Glioblastoma Multiforme with Long-Term Childhood Survival: A Case Report and Systematic Review.

World Neurosurg 2020 Apr 13;139:90-96. Epub 2020 Apr 13.

Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines; Institute for Neurosciences, St. Luke's Medical Center, Quezon City and Global City, Philippines. Electronic address:

Background: Congenital glioblastoma multiforme (cGBM) is an infrequent primary central nervous system tumor occurring within the first few months of life with a reported poor overall prognosis. Our objective was to describe our own clinical case of cGBM and review the literature of cGBM cases with prolonged survival.

Case Description: We report a case of cGBM with prolonged survival at 4 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2020.03.212DOI Listing

Neuro-Ophthalmic Manifestations of Intracranial Malignancies.

J Neuroophthalmol 2020 Apr 6. Epub 2020 Apr 6.

Department of Ophthalmology (CRD, AGL), Cullen Eye Institute, Baylor College of Medicine, Houston, Texas; Blanton Eye Institute (ATK, BAAO, AGL), Houston Methodist Hospital, Houston, Texas; and Departments of Ophthalmology, Neurology, and Neurosurgery (AGL), Weill Cornell Medicine, New York, New York; Department of Ophthalmology (AGL), University of Texas Medical Branch, Galveston, Texas; Department of Ophthalmology (AGL), UT MD Anderson Cancer Center, Houston, Texas; Department of Ophthalmology (AGL), Texas A and M College of Medicine, College Station, Texas; Department of Ophthalmology (AGL), University of Iowa Hospitals and Clinics, Iowa City, Iowa; Department of Ophthalmology (AGL), University of Buffalo, Buffalo, New York.

Background: To describe the various neuro-ophthalmic presentations, key exam features, and clinical findings associated with 5 common primary and secondary intracranial malignancies.

Evidence Acquisition: Retrospective PubMed search and review of published case reports, case series, observational studies, book chapters, and review articles examining the neuro-ophthalmic features of intracranial malignancies including primary glial neoplasms (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNO.0000000000000950DOI Listing

Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS.

Neurol Neuroimmunol Neuroinflamm 2020 May 8;7(3). Epub 2020 Apr 8.

From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.

Objective: To identify coinhibitory immune pathways important in the brain, we hypothesized that comparison of T cells in lesions from patients with MS with tumor-infiltrating T cells (TILs) from patients with glioblastoma multiforme may reveal novel targets for immunotherapy.

Methods: We collected fresh surgical resections and matched blood from patients with glioblastoma, blood and unmatched postmortem CNS tissue from patients with MS, and blood from healthy donors. The expression of TIGIT, CD226, and their shared ligand CD155 as well as PD-1 and PDL1 was assessed by both immunohistochemistry and flow cytometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188477PMC

TP3, an antimicrobial peptide, inhibits infiltration and motility of glioblastoma cells via modulating the tumor microenvironment.

Cancer Med 2020 Apr 7. Epub 2020 Apr 7.

Institute of Medical Science and Technology, National Sun Yat-Sen University, Kaohsiung, Taiwan.

Glioblastoma multiforme (GBM) is a cancer of the central nervous system with limited therapeutic outcomes. Infiltrating cancer cells are the contributing factor to high GBM malignancy. The intracranial brain cancer cell infiltration is a complex cascade involving adhesion, migration, and invasion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3005DOI Listing

Glioblastoma evolving within 10 days following unremarkable computer tomography of the brain: a case report.

Int J Neurosci 2020 Apr 15:1-4. Epub 2020 Apr 15.

Department of Neurology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.

Glioblastoma multiforme might develop radiologically within a few days following unremarkable CT scan of the brain. Glioblastoma multiforme is the most frequent primary brain tumor. Initial presentations are diverse, including headache, seizures and transient or persistent neurological deficits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00207454.2020.1753730DOI Listing

Ac- and Bi-Substance P Analogues for Glioma Therapy.

Semin Nucl Med 2020 Mar;50(2):141-151

Department of Neurosurgery, Bern and University of Basel, Switzerland.

Within the last decades, there has been no major improvement in treatment of patients with glioma, especially with glioblastoma multiforme (GBM) which is related to specific features of this tumor type, such as heterogeneity at the macroscopic, microscopic and genetic level, the infiltrative nature of tumors and the obstacle of the brain-blood barrier which limits the accessability of most drugs. The current standard of care is surgical resection, followed by radio- and chemotherapy. After first-line treatment of the primary lesion, tumor recurrence is diagnosed in virtually all GBM patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semnuclmed.2019.11.004DOI Listing

Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy.

Radiat Res 2020 May 5;193(5):407-424. Epub 2020 Mar 5.

Departments of Radiation Oncology.

Radiotherapy, surgery and the chemotherapeutic agent temozolomide (TMZ) are frontline treatments for glioblastoma multiforme (GBM). However beneficial, GBM treatments nevertheless cause anxiety or depression in nearly 50% of patients. To further understand the basis of these neurological complications, we investigated the effects of combined radiotherapy and TMZ chemotherapy (combined treatment) on neurological impairments using a mouse model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1667/RR15540.1DOI Listing

High Expression of CD44 Predicts a Poor Prognosis in Glioblastomas.

Cancer Manag Res 2020 3;12:769-775. Epub 2020 Feb 3.

Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan Province 410008, People's Republic of China.

Purpose: Glioblastoma multiforme (GBM) is the most common of the malignant and invasive gliomas. High grade glioma is prone to relapse and has a poor prognosis. However, there is a big difference in terms of survival time with the same grade glioma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S233423DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006859PMC
February 2020

A Sox2:miR-486-5p Axis Regulates Survival of GBM Cells by Inhibiting Tumor Suppressor Networks.

Cancer Res 2020 Apr 24;80(8):1644-1655. Epub 2020 Feb 24.

Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland.

Glioblastoma multiforme (GBM) and other solid malignancies are heterogeneous and contain subpopulations of tumor cells that exhibit stem-like features. Our recent findings point to a dedifferentiation mechanism by which reprogramming transcription factors Oct4 and Sox2 drive the stem-like phenotype in glioblastoma, in part, by differentially regulating subsets of miRNAs. Currently, the molecular mechanisms by which reprogramming transcription factors and miRNAs coordinate cancer stem cell tumor-propagating capacity are unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-1624DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165043PMC

Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas.

Jpn J Clin Oncol 2020 Mar;50(3):325-332

Department of Neurosurgery, Chinese PLA General Hospital, Beijing, China.

Objective: The 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) was revised to include molecular biomarkers as diagnostic criteria. However, conventional biopsies of gliomas were spatially and temporally limited. This study aimed to determine whether circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) could provide more comprehensive diagnostic information to gliomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyz156DOI Listing

Re-irradiation for recurrent glioblastoma multiforme: a critical comparison of different concepts.

Strahlenther Onkol 2020 May 3;196(5):457-464. Epub 2020 Feb 3.

Department of Radiation Oncology, University Hospital Münster, Albert-Schweitzer Campus 1, 48149, Muenster, Germany.

Purpose: Purpose of this study was to investigate outcome and toxicity of re-irradiation for recurrent primary glioblastoma (rGBM). We evaluated a group of patients with rGBM and identical primary treatment comprising adjuvant radiotherapy (30 × 2 Gy) with concurrent temozolomide (TMZ).

Methods: In this retrospective study of 46 patients, all received adjuvant or definitive normofractionated radiotherapy to a pretreated area, some with concurrent chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00066-020-01585-0DOI Listing

Thalamic aphasia secondary to glioblastoma multiforme.

J Clin Neurosci 2020 Apr 21;74:234-238. Epub 2020 Jan 21.

Department of Neurology, University of Minnesota, Minneapolis, MN, USA. Electronic address:

Background: Thalamic aphasia is an unusual clinical presentation of brain neoplasm with few cases reported. Herein, we present a case of an adult woman with thalamic aphasia due to glioblastoma of the thalamus.

Case Presentation: A 57-year-old female patient presented with difficulty walking, slow speech and cognition and altered mental status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2020.01.063DOI Listing

Effect of early palliative care for patients with glioblastoma (EPCOG): a randomised phase III clinical trial protocol.

BMJ Open 2020 Jan 7;10(1):e034378. Epub 2020 Jan 7.

Department of General Neurosurgery, Faculty of Medicine and University Hospital, Center for Neurosurgery, University of Cologne, Cologne, Germany.

​INTRODUCTION: Randomised controlled trials (RCTs) have shown a positive effect of early integration of palliative care (EIPC) in various advanced cancer entities regarding patients' quality of life (QoL), survival, mood, caregiver burden and reduction of aggressiveness of treatment near the end of life. However, RCTs investigating the positive effect of EIPC for patients suffering from glioblastoma multiforme (GBM) are lacking. After modelling work identifying the specific needs of GBM patients and their caregivers, the aim of this study is to investigate the impact of EIPC in this particular patient group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2019-034378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955518PMC
January 2020

Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study.

Cold Spring Harb Mol Case Stud 2020 Apr 1;6(2). Epub 2020 Apr 1.

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.

Clinical benefit of immune checkpoint blockade in glioblastoma (GBM) is rare, and we hypothesize that tumor clonal evolution and the immune microenvironment are key determinants of response. Here, we present a detailed molecular characterization of the intratumoral and immune heterogeneity in an wild-type, -negative GBM patient who plausibly benefited from anti- therapy with an unusually long 25-mo overall survival time. We leveraged multiplex immunohistochemistry, RNA-seq, and whole-exome data from the primary tumor and three resected regions of recurrent disease to survey regional tumor-immune interactions, genomic instability, mutation burden, and expression profiles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/mcs.a004762DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133743PMC

Histone 2A Family Member J Drives Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Multiforme.

Cancers (Basel) 2019 Dec 30;12(1). Epub 2019 Dec 30.

Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.

Glioblastoma multiforme (GBM) is the most aggressive brain tumor and has a poor prognosis and is poorly sensitive to radiotherapy or temozolomide (TMZ) chemotherapy. Therefore, identifying new biomarkers to predict therapeutic responses of GBM is urgently needed. By using The Cancer Genome Atlas (TCGA) database, we found that the upregulation of histone 2A family member J (H2AFJ), but not other H2AFs, is extensively detected in the therapeutic-insensitive mesenchymal, IDH wildtype, MGMT unmethylated, or non-G-CIMP GBM and is associated with poor TMZ responsiveness independent of radiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12010098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016639PMC
December 2019

Lipid accumulation and oxidation in glioblastoma multiforme.

Sci Rep 2019 Dec 20;9(1):19593. Epub 2019 Dec 20.

Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, Maryland, USA.

Glioblastoma multiforme (GBM) is the most common and lethal primary malignant brain tumor in adults. Despite the multimodal standard treatments for GBM, the median survival is still about one year. Analysis of brain tissues from GBM patients shows that lipid droplets are highly enriched in tumor tissues while undetectable in normal brain tissues, yet the identity and functions of lipid species in GBM are not well understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-55985-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925201PMC
December 2019

Cerebral neoplasm in L-2-hydroxyglutaric aciduria: two different presentations.

Childs Nerv Syst 2019 Dec 19. Epub 2019 Dec 19.

Pediatric Neurology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.

Background: L-2-hydroxyglutaric aciduria (L2HGA) is a rare neurometabolic disorder characterized by a slowly progressive clinical course, psychomotor and mental retardation, macrocephaly, dysarthria, seizures, and cerebellar and extrapyramidal findings. The diagnosis depends on the presentation of increased levels of L-2-hydroxyglutaric acid in the urine, plasma, and cerebrospinal fluids. Patients with L2HGA have an increased risk for the development of cerebral neoplasms which, though rarely, can be the initial presentation of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00381-019-04466-9DOI Listing
December 2019

First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.

Cancer Manag Res 2019 13;11:10463-10476. Epub 2019 Dec 13.

Sarah Cannon Research Institute, Drug Development Unit, Tennessee Oncology, Nashville, TN, USA.

Purpose: This first-in-human Phase I study investigated the safety, pharmacokinetics (PK), pharmacodynamic profile, and preliminary efficacy of CC-115, a dual inhibitor of mammalian target of rapamycin (mTOR) kinase and DNA-dependent protein kinase.

Patients And Methods: Patients with advanced solid or hematologic malignancies were enrolled in dose-finding and cohort expansion phases. In dose-finding, once-daily or twice-daily (BID) ascending oral doses of CC-115 (range: 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S208720DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916675PMC
December 2019

Olfactory function as an independent prognostic factor in glioblastoma.

Neurology 2020 02 12;94(5):e529-e537. Epub 2019 Dec 12.

From the Division of Clinical Neurooncology (S.K., L.L., M.G.), Department of Neurology (C.K.), West German Cancer Center (S.K., L.R., B.S., M.G.), and Department of Neurosurgery (L.R.), University Hospital Essen, University Duisburg-Essen; Division of Clinical Neurooncology, Department of Neurology and Center of Integrated Oncology (S.K., M.N., N.S., U.H., M.G.), and Institute for Medical Biometry, Informatics, and Epidemiology (R.F.), University of Bonn Medical Center; Department of Neuroradiology (E.H.), Goethe University Hospital, Frankfurt Am Main; Department of Otorhinolaryngology, Smell and Taste Clinic (T.H.), TU Dresden; DKFZ-Division Translational Neurooncology at the West German Cancer Center (S.K., B.S., M.G.), German Cancer Research Center (DKFZ), Heidelberg; and German Cancer Consortium (S.K., B.S., M.G.), Partner Site University Hospital Essen, Germany.

Objective: To determine the role of olfactory function in patients with glioblastoma multiforme (GBM) as a prognostic clinical measure.

Methods: In a prospective case-control study, olfactory testing was performed in 73 patients with primary GBM at baseline during first-line treatment and at later follow-ups. An age-matched control cohort consisted of 49 patients with neurologic diseases, excluding those known to affect olfactory function per se. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000008744DOI Listing
February 2020
8.286 Impact Factor

The spectrum of malignancies presenting with neurological manifestations: A prospective observational study.

J Family Med Prim Care 2019 Nov 15;8(11):3726-3735. Epub 2019 Nov 15.

Department of Neurology, King George Medical University, Lucknow, Uttar Pradesh, India.

Introduction: A neurological consultation is needed in nearly 45% of patients suffering from cancer. The present study was planned to evaluate the clinical, radiological and histopathological spectrum of patients with an underlying malignancy and presenting with a neurological complaint.

Materials And Methods: We prospectively evaluated all patients provisionally diagnosed either with a primary or secondary malignancy of the brain on the basis of clinical, radiological and/or histopathological features. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jfmpc.jfmpc_506_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881939PMC
November 2019

Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.

Neuro Oncol 2020 Apr;22(4):539-549

Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: We sought to ascertain the immune effector function of pembrolizumab within the glioblastoma (GBM) microenvironment during the therapeutic window.

Methods: In an open-label, single-center, single-arm phase II "window-of-opportunity" trial in 15 patients with recurrent (operable) GBM receiving up to 2 pembrolizumab doses before surgery and every 3 weeks afterward until disease progression or unacceptable toxicities occurred, immune responses were evaluated within the tumor.

Results: No treatment-related deaths occurred. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158647PMC
April 2020
5.562 Impact Factor

SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT.

FASEB J 2019 12 7;33(12):14171-14184. Epub 2019 Nov 7.

Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan.

Glioblastoma multiforme (GBM) is the most frequently occurring and gravest primary tumor of the CNS in adults. The development of chemoresistance to temozolomide (TMZ), the first-line chemotherapy for GBM, is an important factor contributing to poor treatment outcomes. Down-regulation of -6-methylguanine-DNA methyltransferase (MGMT) expression in GBM cells is an attractive strategy for overcoming TMZ resistance and improving outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.201901021RRDOI Listing
December 2019

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.

Invest New Drugs 2019 Nov 9. Epub 2019 Nov 9.

Canadian Cancer Trials Group, Queen's University, Kingston, ON, K7L3N6, Canada.

The PI3K/AKT/mTOR pathway activation plays a central role in glioblastoma multiforme (GBM) development and progression, and in resistance to anti-cancer therapies. Inhibition of the PI3K pathway has been shown to sensitize cultured glioma cells and tumor xenografts to the effects of temozolomide (TMZ) and radiation. Vistusertib is an oral inhibitor of mTORC1/2 complexes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-019-00875-4DOI Listing
November 2019
2.919 Impact Factor

miR-802 inhibits the proliferation, invasion, and epithelial-mesenchymal transition of glioblastoma multiforme cells by directly targeting SIX4.

Cell Biochem Funct 2020 Jan 8;38(1):66-76. Epub 2019 Nov 8.

Department of Neurosurgery, Nanjing Medical University Affiliated Changzhou No.2 People's Hospital, Changzhou, China.

It is well known that the sine oculis homeobox 4 (SIX4) expression is very relevant to the progression of multiple cancers. Moreover, we found that miR-802 could directly target the SIX4. However, the precise mechanism of miR-802 in glioblastoma multiforme (GBM) is still unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbf.3451DOI Listing
January 2020
2.005 Impact Factor

Letter to the Editor Regarding "Fluorescein Sodium in Surgical Treatment of Recurrent Glioblastoma Multiforme".

World Neurosurg 2019 08;128:616

Neurosurgical Research Institute, University Hospital of Ioannina, Ioannina, Greece; Department of Neurology, University Hospital of Ioannina, Ioannina, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2019.03.227DOI Listing
August 2019
1 Read

To resect or not to resect? Risks and benefits of surgery in older patients with glioblastoma.

J Geriatr Oncol 2020 May 28;11(4):688-693. Epub 2019 Oct 28.

Department of Neurosurgery, University Hospital Essen, Essen, Germany; German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Introduction: Glioblastoma multiforme (GBM) has a peak incidence in patients older than 65 years. The aim of the present study is to evaluate the impact of surgical strategy on short- and long-term outcomes of older GBM patients.

Methods: A total of 273 older patients (65-84 years) from 2006 to 2014 were operated in our neurosurgical center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2019.10.013DOI Listing
May 2020
1 Read

An Online Calculator for the Prediction of Survival in Glioblastoma Patients Using Classical Statistics and Machine Learning.

Neurosurgery 2020 02;86(2):E184-E192

Computational Neuroscience Outcomes Center (CNOC), Department of Neurosurgery, Brigham and Women's Hospital, School of Medicine, Harvard University, Boston, Massachusetts.

Background: Although survival statistics in patients with glioblastoma multiforme (GBM) are well-defined at the group level, predicting individual patient survival remains challenging because of significant variation within strata.

Objective: To compare statistical and machine learning algorithms in their ability to predict survival in GBM patients and deploy the best performing model as an online survival calculator.

Methods: Patients undergoing an operation for a histopathologically confirmed GBM were extracted from the Surveillance Epidemiology and End Results (SEER) database (2005-2015) and split into a training and hold-out test set in an 80/20 ratio. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuros/nyz403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061165PMC
February 2020
1 Read

Risks and Benefits of Glioblastoma Resection in Older Adults: A Retrospective Austrian Multicenter Study.

World Neurosurg 2020 Jan 24;133:e583-e591. Epub 2019 Sep 24.

Department of Neurosurgery, University Hospital Munich, Ludwig-Maximilians-University, Munich, Germany.

Objective: To assess the prognostic profile, clinical outcome, treatment-associated morbidity, and treatment burden of elderly patients with glioblastoma (GBM) undergoing microsurgical tumor resection as part of contemporary treatment algorithms.

Methods: We retrospectively identified patients with GBM ≥65 years of age who were treated by resection at 2 neuro-oncology centers. Survival was assessed by Kaplan-Meier analyses; log-rank tests identified prognostic factors. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18788750193252
Publisher Site
http://dx.doi.org/10.1016/j.wneu.2019.09.097DOI Listing
January 2020
5 Reads

Hemispheric tumor location and the impact on health-related quality of life, symptomatology, and functional performance outcomes in patients with glioma: an exploratory cross-sectional study.

Disabil Rehabil 2019 Sep 25:1-7. Epub 2019 Sep 25.

Department of Sports Science and Clinical Biomechanics, University of Southern Denmark , Odense , Denmark.

To inform high-quality rehabilitation services, this study investigates if patients with glioma located in the right- or left-hemisphere present with different health-related quality of life, symptomatology, and functional performance in the early disease state. Between 2013 and 2017, 81 adult patients were assessed during the first week of chemo-radiation, following resection. Patients were stratified into two groups depending on a right- or left-hemispheric lesion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09638288.2019.1668486DOI Listing
September 2019
1 Read

Primary Spinal Cord Glioblastoma Multiforme in the Young and Old.

Neurohospitalist 2019 Oct 28;9(4):243-244. Epub 2019 Feb 28.

Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1941874419832443DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739674PMC
October 2019
3 Reads

Elevated CD44 expression predicts poor prognosis in patients with low-grade glioma.

Oncol Lett 2019 Oct 7;18(4):3698-3704. Epub 2019 Aug 7.

Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China.

CD44 is involved in malignant processes including cell motility, tumor growth and angiogenesis. To explore the potential role of CD44 as a prognostic biomarker in low grade gliomas (LGG), the mRNA expression levels of CD44 in tissues from 12 patients with glioma were evaluated by microarray analysis. The mRNA level of CD44 in LGG and glioblastoma multiforme (GBM) were analyzed using datasets downloaded from the publicly available Oncomine database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2019.10728DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732950PMC
October 2019

DAPT, a γ-Secretase Inhibitor, Suppresses Tumorigenesis, and Progression of Growth Hormone-Producing Adenomas by Targeting Notch Signaling.

Front Oncol 2019 27;9:809. Epub 2019 Aug 27.

Key Laboratory of Central Nervous System Injury Research, Center of Brain Tumor of Beijing Institute for Brain Disorders, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.

Advances in the understanding of growth hormone-producing adenomas (GHomas) are ongoing, but current therapy is limited by moderate and variable efficacy and in need of life-long treatment. In this study, the molecular signaling pathway related to GHoma was investigated by proteomics and transcriptomics. The differentially expressed proteins and genes were significantly enriched in Extracellular Matrix-Receptor Interactions, Notch Signaling, Basal Cell Carcinoma Signaling, JAK-STAT3, Wnt Signaling, and Glioblastoma Multiforme Signaling by Ingenuity Pathway Analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00809DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718711PMC
August 2019
3 Reads

GFAP alternative splicing regulates glioma cell-ECM interaction in a DUSP4-dependent manner.

FASEB J 2019 11 31;33(11):12941-12959. Epub 2019 Aug 31.

Department of Translational Neurosciences, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Gliomas are the most common primary brain tumors. Their highly invasive character and the heterogeneity of active oncogenic pathways within single tumors complicate the development of curative therapies and cause poor patient prognosis. Glioma cells express the intermediate filament protein glial fibrillary acidic protein (GFAP), and the level of its alternative splice variant , relative to its canonical splice variant , is higher in grade IV compared with lower-grade and lower malignant glioma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.201900916RDOI Listing
November 2019
5 Reads

The Development and Applications of a Dual Optical Imaging System for Studying Glioma Stem Cells.

Mol Imaging 2019 Jan-Dec;18:1536012119870899

1 Division of Neurosurgery, Department of Surgery, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City.

Glioblastoma multiforme represents one of the deadliest brain tumor types, manifested by a high rate of recurrence and poor prognosis. The presence of glioma stem cells (GSCs) can repopulate the tumor posttreatment and resist therapeutics. A better understanding of GSC biology is essential for developing more effective interventions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1536012119870899DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724491PMC
September 2019
2 Reads
1.962 Impact Factor

Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.

J Neurol Sci 2019 Oct 23;405:116433. Epub 2019 Aug 23.

Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, United States of America. Electronic address:

Background: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. The core of standard of care for newly diagnosed GBM was established in 2005 and includes maximum feasible surgical resection followed by radiation and temozolomide, with subsequent temozolomide with or without tumor-treating fields. Unfortunately, nearly all patients experience a recurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2019.116433DOI Listing
October 2019

An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme.

Oncogene 2019 12 19;38(49):7399-7415. Epub 2019 Aug 19.

Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 510120, Guangzhou, China.

MicroRNAs (miRNAs) have been shown to be involved in the progression and tumor microenvironment of glioblastoma multiforme (GBM). Our previous research has indicated that miR-340-5p has an antitumor effect in vitro. However, the role of miR-340-5p in GBM has not been fully elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-019-0952-xDOI Listing
December 2019
2 Reads

Prognostic significance of contactin 3 expression and associated genes in glioblastoma multiforme.

Oncol Lett 2019 Aug 14;18(2):1863-1871. Epub 2019 Jun 14.

Medical Research Center, The Second Affiliated Clinical College of Chongqing Medical University, The Third People's Hospital of Chengdu, Chengdu, Sichuan 610031, P.R. China.

Contactin 3 (CNTN3) is a member of the contactin family that is primarily expressed in the nervous system. However, to the best of our knowledge, expression of contactin and its role in the development and progression of brain tumours has not been studied. Although glioblastoma multiforme (GBM) is the most common malignant brain tumour, advances in therapeutic options for patients with GBM have been modest due to an incomplete understanding of the molecular mechanisms underlying development and progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2019.10482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607048PMC
August 2019
3 Reads
0.987 Impact Factor

Glioblastoma multiforme restructures the topological connectivity of cerebrovascular networks.

Sci Rep 2019 08 13;9(1):11757. Epub 2019 Aug 13.

Heidelberg University Hospital, Department of Neuroradiology, Heidelberg, 69120, Germany.

Glioblastoma multiforme alters healthy tissue vasculature by inducing angiogenesis and vascular remodeling. To fully comprehend the structural and functional properties of the resulting vascular network, it needs to be studied collectively by considering both geometric and topological properties. Utilizing Single Plane Illumination Microscopy (SPIM), the detailed capillary structure in entire healthy and tumor-bearing mouse brains could be resolved in three dimensions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-47567-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692362PMC
August 2019
3 Reads

Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients.

Br J Neurosurg 2019 Aug 13:1-7. Epub 2019 Aug 13.

a Department of Neurosurgery, Faculty of Medicine, Heinrich-Heine-University Düsseldorf , Düsseldorf , Germany.

: Vaccination therapy using tumour antigen-loaded, autologous dendritic cells (DC) is a promising therapeutic approach alongside standard treatment for glioblastoma (GBM). However, reliable diagnostic criteria regarding therapy monitoring are not established. Here, we analysed the impact of additional F-fluoroethyl-tyrosine positron emission tomography (F-FET PET) imaging following DC vaccination therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02688697.2019.1639615DOI Listing
August 2019
3 Reads

Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics.

Cells 2019 08 9;8(8). Epub 2019 Aug 9.

Centre of Toxicology Science and Research, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece.

Glioblastoma multiforme is the most aggressive malignant tumor of the central nervous system. Due to the absence of effective pharmacological and surgical treatments, the identification of early diagnostic and prognostic biomarkers is of key importance to improve the survival rate of patients and to develop new personalized treatments. On these bases, the aim of this review article is to summarize the current knowledge regarding the application of molecular biology and proteomics techniques for the identification of novel biomarkers through the analysis of different biological samples obtained from glioblastoma patients, including DNA, microRNAs, proteins, small molecules, circulating tumor cells, extracellular vesicles, etc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells8080863DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721640PMC
August 2019
4 Reads

A network-based analysis for mining the risk pathways in glioblastoma.

Oncol Lett 2019 Sep 9;18(3):2712-2717. Epub 2019 Jul 9.

Department of Neurology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.

The most malignant type of brain tumour is glioblastoma multiforme (GBM). Patients with GBM often have a poor prognosis, as a result of incomplete or inaccurate diagnoses. Regulatory pathways have been demonstrated to serve important roles in complex human diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2019.10598DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676740PMC
September 2019
7 Reads

Long noncoding RNA HAS2-AS1 promotes tumor progression in glioblastoma via functioning as a competing endogenous RNA.

J Cell Biochem 2020 Jan 5;121(1):661-671. Epub 2019 Aug 5.

Department of Neurology, Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma Neurorepair and Regeneration in Central Nervous System, Ministry of Education, Tianjin, China.

Glioblastoma multiforme (GBM) is a refractory tumor with poor prognosis and requires more effective treatment regimens. It has been confirmed that long noncoding RNAs (lncRNAs) substantially regulate various human disease including GBM. However, the biological roles and its underlying molecular mechanisms still need to be further investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.29313DOI Listing
January 2020
2 Reads

Small GTPase RHOE/RND3, a new critical regulator of NF-κB signalling in glioblastoma multiforme?

Cell Prolif 2019 Sep 22;52(5):e12665. Epub 2019 Jul 22.

Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.

Objectives: Abnormal activation of NF-κB signalling is a major mechanism of apoptosis resistance in glioblastoma multiforme (GBM). Therefore, better understanding of the regulation of NF-κB signalling has a significant impact for GBM therapy. Here, we uncovered a critical role of the small GTPase RND3 in regulating the p65 subunit of NF-κB and NF-κB signalling in GBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cpr.12665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797521PMC
September 2019
1 Read